566-48-3 Estrogen Steroid Hormone Formestane Powder Sex Enhancement Powder

566-48-3 Estrogen Steroid Hormone Formestane Powder Sex Enhancement Powder

Formestane/Lentaron Basic Info:
Product Name:Formestane
CAS No: 566-48-3
Einecs No: 219-112-8
MF: C19H26O3
MW: 302.41.
Purity: 99.3%
Appearance: white crystalline powder
Formestane/Lentaron COA

Description:

Formestane Is the second generation of irreversible steroid aromatase inhibitors. It inhibits the aromatase responsible for converting androgen into estrogen, thereby preventing estrogen production. Breast cancer may be estrogen-sensitive or insensitive. Most breast cancers are estrogen-sensitive. Estrogen-sensitive breast cancer cells are dependent on estrogenic activity. Therefore, removal of estrogen from the body can become an effective treatment for hormone-sensitive breast cancer.

Formestane is dedicated to the treatment of postmenopausal women. Unlike premenopausal women who produce the most estrogen in the ovaries, postmenopausal women produce most estrogens in peripheral tissues with the help of aromatases. Methanesulfonamide aromatase inhibitors can help reduce the production of estrogen by blocking aromatase (ie, attached to mammary gland tissue) in peripheral tissues to treat hormone-sensitive breast cancer.

Formestane is Also known as lentaron, is an anti-cancer drug, mainly used for the treatment of advanced breast cancer in postmenopausal women, also effective for prostate cancer.

Methanesulfonic acid is a androstenedione derivative, an aromatic enzyme inhibitor with amino hydroxyethyl amide, is a hormone antineoplastic agent. Under physiological conditions, it may competitively inhibit the synthesis of enzymes, resulting in reduced estrogen biosynthesis in the tissue, and then it works in cancer. When tumor tissue growth depends on the presence of estrogen, it is necessary to eliminate tumor estrogen-mediated growth stimuli in order to inhibit tumor growth.

The product is more selective than amino isoflavones, and its activity is amino-hydroxyethylamine 100 to 1000 times, does not inhibit the synthesis of adrenal hormones, without the need to add cortisone and so on. The in vitro inhibition of the product's aromatase is 60 times stronger than that of aminosuccinimide.

When it is used alone, when it is combined with goserelin (gonadotropin-releasing hormone agonist), the drug does not significantly reduce premenopausal estrogen levels in women's blood, and estrogen inhibition in premenopausal women The effect is greater than that of goserelin alone using methanesulfonic acid with other aromatase inhibitors without cross resistance, which does not have side effects of aminoglucan.

After oral administration, it is rapidly absorbed by the gastrointestinal tract, the plasma concentration of the peak time of 1 ~ 1.5 hours, but the individual peak concentration difference; intramuscular injection, can be accumulated in the injection site and slowly absorbed. It performs a biphasic elimination process, the initial elimination half-life of 2 to 4 days, the terminal elimination half-life of 5 to 10 days. After oral administration mainly in the liver metabolism, uridine excretion of glycoside metabolites in the form of existence.